Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MRI Shows High Sensitivity In Breast Cancer Detection – NCI-Funded Study

This article was originally published in The Gray Sheet

Executive Summary

Magnetic resonance imaging, unlike mammography, appears to offer high sensitivity for women with dense breasts, according to a study published in the Dec. 8 issue of the Journal of the American Medical Association

You may also be interested in...

CT Laser Mammography Developer Braces For Second PMA, User Fee Charge

Imaging Diagnostic Systems maintains that no new clinical studies are needed to support a second PMA filing for its CTLM computed tomography laser mammography system

JAMA Study, Editorial Caution Routine Use Of MRI To Detect Breast Cancer

Future studies need to establish whether MRI as a breast cancer detection tool corresponds with reductions in mortality before it is applied broadly to at-risk patients, a JAMA study and accompanying editorial conclude

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts